Novartis AG, Amgen Inc., and Seattle Genetics Inc. have all had a common experience in 2018: each sponsor has received US FDA approval for a supplemental application less than a month after completing the submission – before they would normally even have been notified that the filing was accepted.
Seattle Genetics is the current record holder, with the Nov. 16 approval by FDA of a new indication for Adcetris...








